Monitoring of structure and function in early cystic fibrosis lung disease

Sarath C. Ranganathan, Stephanie D. Davis, Margaret Rosenfeld

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Concurrent with improving survival in cystic fibrosis (CF), lung function has also steadily improved. Forced expiratory volume in one second (FEV 1), the measure of airway obstruction most widely monitored in patients with CF, often does not fall below the normal range until late adolescence. Clearly, FEV1 is losing relevance for clinicians monitoring lung disease in children with CF, as it is frequently normal, declines slowly, and cannot be measured by conventional techniques in children <6 years of age. As clinicians increasingly aim to identify and treat early CF lung disease before irreversible structural airway damage occurs, there is a compelling need for better tools with which to monitor for early lung structural and physiologic abnormalities in our youngest CF patients. Three promising measures are infant and preschool lung function testing, chest computed tomography, and multiple breath washout measures of the lung clearance index. The current state of these tests as they relate to the clinical monitoring of early CF lung disease is reviewed, and improvements on the horizon that may allow them to be adopted in clinical practice explained.

Original languageEnglish (US)
Pages (from-to)133-137
Number of pages5
JournalPediatric, Allergy, Immunology, and Pulmonology
Volume24
Issue number3
DOIs
StatePublished - Sep 1 2011

Fingerprint

Cystic Fibrosis
Lung Diseases
Forced Expiratory Volume
Airway Obstruction
Reference Values
Lung
Survival

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

Monitoring of structure and function in early cystic fibrosis lung disease. / Ranganathan, Sarath C.; Davis, Stephanie D.; Rosenfeld, Margaret.

In: Pediatric, Allergy, Immunology, and Pulmonology, Vol. 24, No. 3, 01.09.2011, p. 133-137.

Research output: Contribution to journalArticle

@article{2193989dd7ab43248f8c1c27bcd1d535,
title = "Monitoring of structure and function in early cystic fibrosis lung disease",
abstract = "Concurrent with improving survival in cystic fibrosis (CF), lung function has also steadily improved. Forced expiratory volume in one second (FEV 1), the measure of airway obstruction most widely monitored in patients with CF, often does not fall below the normal range until late adolescence. Clearly, FEV1 is losing relevance for clinicians monitoring lung disease in children with CF, as it is frequently normal, declines slowly, and cannot be measured by conventional techniques in children <6 years of age. As clinicians increasingly aim to identify and treat early CF lung disease before irreversible structural airway damage occurs, there is a compelling need for better tools with which to monitor for early lung structural and physiologic abnormalities in our youngest CF patients. Three promising measures are infant and preschool lung function testing, chest computed tomography, and multiple breath washout measures of the lung clearance index. The current state of these tests as they relate to the clinical monitoring of early CF lung disease is reviewed, and improvements on the horizon that may allow them to be adopted in clinical practice explained.",
author = "Ranganathan, {Sarath C.} and Davis, {Stephanie D.} and Margaret Rosenfeld",
year = "2011",
month = "9",
day = "1",
doi = "10.1089/ped.2011.0079",
language = "English (US)",
volume = "24",
pages = "133--137",
journal = "Pediatric, Allergy, Immunology, and Pulmonology",
issn = "2151-321X",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Monitoring of structure and function in early cystic fibrosis lung disease

AU - Ranganathan, Sarath C.

AU - Davis, Stephanie D.

AU - Rosenfeld, Margaret

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Concurrent with improving survival in cystic fibrosis (CF), lung function has also steadily improved. Forced expiratory volume in one second (FEV 1), the measure of airway obstruction most widely monitored in patients with CF, often does not fall below the normal range until late adolescence. Clearly, FEV1 is losing relevance for clinicians monitoring lung disease in children with CF, as it is frequently normal, declines slowly, and cannot be measured by conventional techniques in children <6 years of age. As clinicians increasingly aim to identify and treat early CF lung disease before irreversible structural airway damage occurs, there is a compelling need for better tools with which to monitor for early lung structural and physiologic abnormalities in our youngest CF patients. Three promising measures are infant and preschool lung function testing, chest computed tomography, and multiple breath washout measures of the lung clearance index. The current state of these tests as they relate to the clinical monitoring of early CF lung disease is reviewed, and improvements on the horizon that may allow them to be adopted in clinical practice explained.

AB - Concurrent with improving survival in cystic fibrosis (CF), lung function has also steadily improved. Forced expiratory volume in one second (FEV 1), the measure of airway obstruction most widely monitored in patients with CF, often does not fall below the normal range until late adolescence. Clearly, FEV1 is losing relevance for clinicians monitoring lung disease in children with CF, as it is frequently normal, declines slowly, and cannot be measured by conventional techniques in children <6 years of age. As clinicians increasingly aim to identify and treat early CF lung disease before irreversible structural airway damage occurs, there is a compelling need for better tools with which to monitor for early lung structural and physiologic abnormalities in our youngest CF patients. Three promising measures are infant and preschool lung function testing, chest computed tomography, and multiple breath washout measures of the lung clearance index. The current state of these tests as they relate to the clinical monitoring of early CF lung disease is reviewed, and improvements on the horizon that may allow them to be adopted in clinical practice explained.

UR - http://www.scopus.com/inward/record.url?scp=80053344896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053344896&partnerID=8YFLogxK

U2 - 10.1089/ped.2011.0079

DO - 10.1089/ped.2011.0079

M3 - Article

AN - SCOPUS:80053344896

VL - 24

SP - 133

EP - 137

JO - Pediatric, Allergy, Immunology, and Pulmonology

JF - Pediatric, Allergy, Immunology, and Pulmonology

SN - 2151-321X

IS - 3

ER -